Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats

References

• Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. Plos One. 2013;8:e57479. doi:10.1371/journal.pone.0057479.
   PubMed Web of Science ®Google Scholar
• McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther. 2012;11:582–13. doi:10.1158/1535-7163.MCT-11-0820.
   PubMed Web of Science ®Google Scholar
• Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, et al. A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses. Science. 2016;354:350–54. doi:10.1126/science.aag3267.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. Mabs. 2017;9:182–212. doi:10.1080/19420862.2016.1268307.
   PubMed Web of Science ®Google Scholar
• Dickopf S, Georges GJ, Brinkmann U. Format and geometries matter: structure-based design defines the functionality of bispecific antibodies. Comput Struct Biotechnol J. 2020;18:1221–27. doi:10.1016/j.csbj.2020.05.006.
   PubMed Web of Science ®Google Scholar
• Kast F, Schwill M, Stüber JC, Pfundstein S, Nagy-Davidescu G, Rodríguez JMM, Seehusen F, Richter CP, Honegger A, Hartmann KP, et al. Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action. Nat Commun. 2021;12:3790. doi:10.1038/s41467-021-23948-6.
   PubMed Web of Science ®Google Scholar
• Croasdale R, Wartha K, Schanzer JM, Kuenkele KP, Ries C, Mayer K, Gassner C, Wagner M, Dimoudis N, Herter S, et al. Development of tetravalent IgG1 dual targeting IGF-1R–egfr antibodies with potent tumor inhibition. Arch Biochem Biophys. 2012;526:206–18. doi:10.1016/j.abb.2012.03.016.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585–608. doi:10.1038/s41573-019-0028-1.
   PubMed Web of Science ®Google Scholar
• Li Y. A brief introduction of IgG-like bispecific antibody purification: methods for removing product-related impurities. Protein Expr Purif. 2019;155:112–19. doi:10.1016/j.pep.2018.11.011.
   PubMed Web of Science ®Google Scholar
• Chen SW, Zhang W. Current trends and challenges in the downstream purification of bispecific antibodies. Antib Ther. 2021;4:73–88. doi:10.1093/abt/tbab007.
   PubMedGoogle Scholar
• Dengl S, Mayer K, Bormann F, Duerr H, Hoffmann E, Nussbaum B, Tischler M, Wagner M, Kuglstatter A, Leibrock L, et al. Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices. Nat Commun. 2020;11:4974. doi:10.1038/s41467-020-18477-7.
   PubMed Web of Science ®Google Scholar
• Wörn A, Plückthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol. 2001;305:989–1010. doi:10.1006/jmbi.2000.4265.
   PubMed Web of Science ®Google Scholar
• Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR. Mabs. 2009;1:128–41. doi:10.4161/mabs.1.2.7631.
   PubMed Web of Science ®Google Scholar
• Cao M, Wang C, Chung WK, Motabar D, Wang J, Christian E, Lin S, Hunter A, Wang X, Liu D. Characterization and analysis of scFv-IgG bispecific antibody size variants. Mabs. 2018;10:1236–47. doi:10.1080/19420862.2018.1505398.
   PubMed Web of Science ®Google Scholar
• Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–97. doi:10.1146/annurev-biochem-063011-092449.
   PubMed Web of Science ®Google Scholar
• Madsen AV, Mejias-Gomez O, Pedersen LE, Skovgaard K, Kristensen P, Goletz S. Immobilization-Free binding and affinity characterization of higher order bispecific antibody complexes using size-based microfluidics. Anal Chem. 2022;94:13652–58. doi:10.1021/acs.analchem.2c02705.
   PubMed Web of Science ®Google Scholar
• Irving B, Chiu H, Maecker H, Mariathasan S, Lehar S, Wu Y, Cheung J., inventors; Genentech, asignee. Anti-PD-L1 Antibodies, Compositions and Articles of Manufacture. United States patent US8217149B2. 2012 July 10.
   Google Scholar
• Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558–62. doi:10.1038/nature13904.
   PubMed Web of Science ®Google Scholar
• Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421:756–60. doi:10.1038/nature01392.
   PubMed Web of Science ®Google Scholar
• Zhang F, Qi X, Wang X, Wei D, Wu J, Feng L, Cai H, Wang Y, Zeng N, Xu T, et al. Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget. 2017;8:90215–24. doi:10.18632/oncotarget.21652.
   PubMedGoogle Scholar
• Vaneycken I, Devoogdt N, Van Gassen N, Vincke C, Xavier C, Wernery U, Muyldermans S, Lahoutte T, Caveliers V. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. Faseb J. 2011;25:2433–46. doi:10.1096/fj.10-180331.
   PubMed Web of Science ®Google Scholar
• Dimasi N, Fleming R, Wu H, Gao C. Molecular engineering strategies and methods for the expression and purification of IgG1-based bispecific bivalent antibodies. Methods. 2019;154:77–86. doi:10.1016/j.ymeth.2018.08.004.
   PubMed Web of Science ®Google Scholar
• Yanakieva D, Pekar L, Evers A, Fleischer M, Keller S, Mueller-Pompalla D, Toleikis L, Kolmar H, Zielonka S, Krah S. Beyond bispecificity: controlled Fab arm exchange for the generation of antibodies with multiple specificities. Mabs. 2022;14:2018960. doi:10.1080/19420862.2021.2018960.
   PubMed Web of Science ®Google Scholar
• Wu X, Sereno AJ, Huang F, Lewis SM, Lieu RL, Weldon C, Torres C, Fine C, Batt MA, Fitchett JR, et al. Fab-based bispecific antibody formats with robust biophysical properties and biological activity. Mabs. 2015;7:470–82. doi:10.1080/19420862.2015.1022694.
   PubMed Web of Science ®Google Scholar
• Lavoisier A, Schlaeppi JM. Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection. Mabs. 2015;7:77–83. doi:10.4161/19420862.2014.985544.
   PubMed Web of Science ®Google Scholar
• Smilgies DM, Folta-Stogniew E. Molecular weight-gyration radius relation of globular proteins: a comparison of light scattering, small-angle X-ray scattering and structure-based data. J Appl Crystallogr. 2015;48:1604–06. doi:10.1107/S1600576715015551.
   PubMed Web of Science ®Google Scholar
• Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, et al. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci U S A. 2017;114:944–49. doi:10.1073/pnas.1616408114.
   PubMed Web of Science ®Google Scholar
• Kim SH, Yoo HJ, Park EJ, Na DH. Nano differential scanning fluorimetry-based thermal stability screening and optimal buffer selection for immunoglobulin G. Pharmaceuticals. 2022;15:29. doi:10.3390/ph15010029.
   Web of Science ®Google Scholar
• Ionescu RM, Vlasak J, Price C, Kirchmeier M. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci. 2008;97:1414–26. doi:10.1002/jps.21104.
   PubMed Web of Science ®Google Scholar
• Feige MJ, Hendershot LM, Buchner J. How antibodies fold. Trends Biochem Sci. 2010;35:189–98. doi:10.1016/j.tibs.2009.11.005.
   PubMed Web of Science ®Google Scholar
• Bertz M, Buchner J, Rief M. Mechanical Stability of the Antibody Domain CH3 Homodimer in Different Oxidation States. J Am Chem Soc. 2013;135:15085–91. doi:10.1021/ja405076j.
   PubMed Web of Science ®Google Scholar
• Pedersen ME, Haegebaert RMS, Østergaard J, Jensen H. Size-based characterization of adalimumab and TNF-α interactions using flow induced dispersion analysis: assessment of avidity-stabilized multiple bound species. Sci Rep. 2021;11:4754. doi:10.1038/s41598-021-84113-z.
   PubMed Web of Science ®Google Scholar
• Lua WH, Ling WL, Yeo JY, Poh JJ, Lane DP, Gan SKE. The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: impact on antibody production and antigen-binding. Sci Rep. 2018;8:718. doi:10.1038/s41598-017-18892-9.
   PubMed Web of Science ®Google Scholar
• Tan S, Liu K, Chai Y, Zhang CWH, Gao S, Gao GF, Qi J. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell. 2018;9:135–39. doi:10.1007/s13238-017-0412-8.
   PubMed Web of Science ®Google Scholar
• Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69:4941–44. doi:10.1158/0008-5472.CAN-09-0547.
   PubMed Web of Science ®Google Scholar
• Goletz C, Lischke T, Harnack U, Schiele P, Danielczyk A, Rühmann J, Goletz S. Glyco-engineered anti-human programmed death-ligand 1 antibody mediates stronger CD8 T cell activation than its normal glycosylated and non-glycosylated counterparts. Front Immunol. 2018;9:1614. doi:10.3389/fimmu.2018.01614.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lee AG, Nguyen AW, Maynard JA. An antibody Fc engineered for conditional antibody-dependent cellular cytotoxicity at the low tumor microenvironment pH. J Biol Chem. 2022;298:101798. doi:10.1016/j.jbc.2022.101798.
   PubMed Web of Science ®Google Scholar
• Guo C, Chen F, Xiao Q, Catterall HB, Robinson JH, Wang Z, Mock M, Hubert R. Expression liabilities in a four-chain bispecific molecule. Biotechnol Bioeng. 2021;118:3744–59. doi:10.1002/bit.27850.
   PubMed Web of Science ®Google Scholar
• Tustian AD, Endicott C, Adams B, Mattila J, Bak H. Development of purification processes for fully human bispecific antibodies based upon modification of protein a binding avidity. Mabs. 2016;8:828–38. doi:10.1080/19420862.2016.1160192.
   PubMed Web of Science ®Google Scholar
• Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, Ng SB, Born T, Retter M, Manchulenko K, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem. 2010;285:19637–46. doi:10.1074/jbc.M110.117382.
   PubMed Web of Science ®Google Scholar
• Atwell S, Ridgway JBB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol. 1997;270:26–35. doi:10.1006/jmbi.1997.1116.
   PubMed Web of Science ®Google Scholar
• Moore GL, Bautista C, Pong E, Nguyen DHT, Jacinto J, Eivazi A, Muchhal US, Karki S, Chu SY, Lazar GA. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. Mabs. 2011;3:546–57. doi:10.4161/mabs.3.6.18123.
   PubMed Web of Science ®Google Scholar
• De Nardis C, Hendriks LJA, Poirier E, Arvinte T, Gros P, Bakker ABH, De Kruif J. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1. J Biol Chem. 2017;292:14706–17. doi:10.1074/jbc.M117.793497.
   PubMed Web of Science ®Google Scholar
• Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, Bairoch A. Protein Identification and Analysis Tools on the ExPASy Server. Proteomics Protoc Handb. 2005;1:571–607.
   Google Scholar